Have a personal or library account? Click to login
Quality of Life in Primary Insomnia: Three-week Treatment With Zolpidem Vs. Lorazepam Cover

Quality of Life in Primary Insomnia: Three-week Treatment With Zolpidem Vs. Lorazepam

Open Access
|Oct 2017

References

  1. 1. Lloyd GG (1995). Psychiatry. In Edwards CRW, Bouchier IAD, Haslett C, Chilvers ER, eds. Davidson’s Principles and Practice of Medicine, 978-1019. 17th ed. Edinburgh: Churchil Livingstone.
  2. 2. Lustbader AS, Morgan C, Pelayo R, Vasquez LS, Yuen K (1997). Insomnia. In Rucker LM, ed. Essentials of adult ambulatory care 607-17. Baltimore: Williams and Wilkins.
  3. 3. Ohayon MM: Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res 1997; 31: 333-46.10.1016/S0022-3956(97)00002-2
  4. 4. Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE: Cognitive behavioral therapy for treatment of chronic primary insomnia. A randomized controlled trial. JAMA 2001; 285: 1856-64.10.1001/jama.285.14.1856
  5. 5. Lee-Chiong T (2008). Sleep Medicine- Essentials and Review, pp 73-133. Oxford University press.
  6. 6. Buysse JD: Chronic Insomnia. Am J Psychiatry 2008; 165(6): 678-686.10.1176/appi.ajp.2008.08010129
  7. 7. Pigeon RW: Diagnosis, prevalence, pathways, consequences & treatment of insomnia. Indian J Med Res 2010; 131: 321-332.
  8. 8. Đukić Dejanović SM, Milovanović D, Ravanić D. et al.(2003). Nesanice- zdravstveni i ekonomski problem savremenog društva. Medicinski fakultet Kragujevac.
  9. 9. Roth T & Ancoli-Israel S: Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation survey. II. Sleep 1999; 22: 354-8.
  10. 10. Simon GE & VonKorff M:Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997; 154: 1417-23.10.1176/ajp.154.10.1417
  11. 11. Balter MB: Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992; 53 (suppl 12): 34-9.
  12. 12. Longmore M, Wilkinson I, Torok E (2001). Oxford handbook of clinical medicine. 5th ed. Oxford: Oxford University Press.
  13. 13. Kyle SD, Morgan K, Espie CA: Insomnia and health-related quality of life. Sleep Medicine Reviews 2010; 14: 69-82.10.1016/j.smrv.2009.07.004
  14. 14. Hauri PJ: Can we mix behavioral therapy with hypnotics when treating insomniacs? Sleep 1997; 20: 1111-8.10.1093/sleep/20.12.1111
  15. 15. Ashton H: The treatment of benzodiazepine dependence. Addiction. 1994; 89(11): 1535-41.10.1111/j.1360-0443.1994.tb03755.x
  16. 16. Seltzer JK, Kurt TL, Knodel LC, Dean B, Burch C: Texas Medicaid Vendor Drug Program Drug Utilization Review Board. Drug utilization review of sedative/hypnotic agents in Texas Medicaid patients. J Am Pharm Assoc 2000; 40: 495-9.10.1016/S1086-5802(15)30395-8
  17. 17. Buysse DJ, Reynolds CF, Kupfer DJ, Thorpy MJ, Bixler E, Manfredi R et al.: Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV Field Trial. Sleep 1994; 17: 630-7.10.1093/sleep/17.7.630
  18. 18. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.
  19. 19. Soldatos CR, Dikeos DG, Paparrigopoulos TJ: Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 2000; 48: 555-60.10.1016/S0022-3999(00)00095-7
  20. 20. Bliwise DL, Seidel WF, Cohen SA, Bliwise NG, Dement WC: Profile of mood states changes during and after 5 weeks of nightly triazolam administration. J Clin Psychiatry 1988; 49(9): 349-55.
  21. 21. Zisapel N & Nir T: Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale. J Sleep Res 2003; 12: 291-298.10.1046/j.0962-1105.2003.00365.x14633240
  22. 22. Morin CM, Stone J, Trinkle D, Mercer J, Remsberg S: Dysfunctional beliefs and attitudes about sleep among older adults with and without insomnia complaints. Psychol Aging. 1993; 8(3): 463-7.10.1037/0882-7974.8.3.463
  23. 23. Whitehead S & Ali S: Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010; 96: 5-21.10.1093/bmb/ldq03321037243
  24. 24. Slobogean GP, O’Brien PJ, Brauer CA: Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures. Acta Orthop 2010; 81(2): 256-62.10.3109/17453671003587119289534820148647
  25. 25. Sakai M, Shimbo T, Omata K, Takahashi Y, SatomuraK, Kitamura T et al.: Cost-effectiveness of gargling for the prevention of upper respiratory tract infections. BMC Health Serv Res 2008; 8: 258.10.1186/1472-6963-8-258265187419087312
  26. 26. Yen ZS, Davis MA, Chen SC, Chen WJ: A cost-effectiveness analysis of treatment strategies for acute uncomplicated pyelonephritis in women. Acad Emerg Med 2003; 10(4): 309-14.
  27. 27. Sajid MS, Tonsi A, Baig MK: Health-related quality of life measurement. Int J Health Care Qual Assur. 2008; 21(4): 365-73.10.1108/0952686081088016218785462
  28. 28. Mihajlović G, Jovanović-Mihajlović N, Radmanović B, Radonjić K, Djukić-Dejanović S, Janković S et al.: Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone. Srp Arh Celok Lek. 2011; 139 (1): 36-40.10.2298/SARH11S1036M
  29. 29. Testa MA & Simonson DC: Assesment of quality-of-life outcomes. N Engl J Med 1996; 334(13): 835-40. 10.1056/NEJM1996032833413068596551
  30. 30. Kelly F, Delahaye C, Gal M: Quality of life in insomnia - results of validation studies for a specifically designed questionnaire. JAMA 1993; 3:21-6.
  31. 31. Goldenberg F, Hindmarch I, Joyce CRB, Legal M, Partinen M, Pilate C: Zopiclone, sleep and health-related quality-of-life. Human Psychopharmacology- Clinical and Experimental 1994; 9: 245-51.10.1002/hup.470090403
  32. 32. Manuel DG, Schultz SE, Kopec JA: GroupMeasuringthe Health Burden of Chronic Disease and Injury Using Health Adjusted Life Expectancy and the Health Utilities Index. Journal of Epidemiology and Community Health 2002; 56(11): 843-850.10.1136/jech.56.11.843173204412388577
  33. 33. Moksin Mićić A (2005). Kvalitet života u rubnim zonoma grodova u Evropskoj uniji i Srbiji. In Održivi razvoj i njegovo okruženje 19-33. Beograd: Institut za arhitekturu i urbanizom Srbije.
  34. 34. Arsovski S: Put od kvaliteta do kvaliteta života. Zbornik radova Festival kvaliteta 2005; 32. nacionalna konferencija o kvalitetu, Kragujevac, 2005; 1: 3-16.
  35. 35. Radojlović J & Petrović NM:Stres svuda oko nas - prevladavanje hroničnog stresa. Zdravstvena zaštita 2011; 40(2): 79-82.
  36. 36. Roberts H: Serbia and Montenegro’s state services behind rest of Europe. Lancet 2003; 361(9354): 316-7.10.1016/S0140-6736(03)12367-7
  37. 37. Garfield R: Economic sanctions on Yugoslavia. Lancet 2001; 358(9281): 580.10.1016/S0140-6736(01)05713-0
  38. 38. Torrance GW, Feeny D, Furlong W: Visual Analog Scales: Do They Have a Role in the Measurement of Preferences for Health States? Med Decis Making 2001; 21: 329-334.10.1177/02729890122062622
  39. 39. Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, et al.: Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000; 23: 1087-96.10.1093/sleep/23.8.1h
  40. 40. Hajak G, Cluydts R, Declerck A, Estivill SE, Middleton A, Sonka K, et al.: Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a largescale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol 2002; 17: 9-17.10.1097/00004850-200201000-0000211800507
  41. 41. Martin SA, Aikens JE, Chervin RD: Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Med Rev 2004; 8: 63-72.10.1016/j.smrv.2003.08.00115062211
  42. 42. Leger D, Scheuermaier K, Philip P, Paillard M, GuilleminaultC: SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom Med. 2001; 63:49-55.10.1097/00006842-200101000-0000611211064
  43. 43. Reynolds CF, Buysse DJ, Kupfer DJ (1995). Disordered sleep: developmental and biopsychosocial perspectives on the diagnosis and treatment of persistent insomnia. In Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress 1617-29. New York: Raven Press.
  44. 44. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T; ZOLONG Study Group: Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008; 31(1): 79-90.10.1093/sleep/31.1.79222555218220081
  45. 45. Morin CM, Vallieres A, Guay B, Ivers H, Savard J, Merette C et al.: Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009; 301(19): 2005-1510.1001/jama.2009.682305062419454639
DOI: https://doi.org/10.1515/sjecr-2016-0077 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454
Language: English
Page range: 231 - 237
Submitted on: Jun 12, 2016
Accepted on: Jun 26, 2016
Published on: Oct 19, 2017
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2017 Vladimir Janjic, Branimir Radmanovic, Zoran Bukumiric, Slavica Djukic Dejanovic, Nemanja Muric, Milica Borovcanin, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.